Nebulized colistin for non-cystic fibrosis bronchiectasis: Déjà vu all over again?

American Journal of Respiratory and Critical Care Medicine

Volumn 189, Issue 10, 2014, Pages 1151-1152

  Metersky, Mark L ^a   O'Donnell, Anne E ^b  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; MACROLIDE;

ANTIMICROBIAL THERAPY; BACTERIAL LOAD; BRONCHIECTASIS; DISEASE EXACERBATION; DRUG DELIVERY SYSTEM; EDITORIAL; HOME NEBULIZER; HUMAN; MEDICATION COMPLIANCE; NEBULIZATION; NONCYSTIC FIBROSIS BRONCHIECTASIS; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; COLISTIN; FEMALE; HUMANS; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84901045169     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201404-0638ED     Document Type: Editorial

References (12)

1. O'Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 1998;113:1329-1334.
2. Bilton D, Henig N, Morrissey B, Gotfried M. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 2006;130: 1503-1510.
3. Wu Q, Shen W, Cheng H, Zhou X. Long-term macrolides for non-cystic fibrosis bronchiectasis: a systematic review and meta-analysis. Respirology 2014;19:321-329.
4. Barker A, O'Donnell A, Thompson P, Flume P, Ruzi J, de Gracia J, Boersma WG, Polverino E, Shao L, Zhang J, et al. Two phase 3 placebo-controlled trials of aztreonam lysine for inhalation (AZLI) for non-cystic fibrosis bronchiectasis (NCFB). Eur Respir J 2013;42:877s.
5. Bilton D, Daviskas E, Anderson SD, Kolbe J, King G, Stirling RG, Thompson BR, Milne D, Charlton B; B301 Investigators. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest 2013;144:215-225.
6. Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014;189: 975-982.
7. Pasteur MC, Bilton D, Hill AT; British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010;65:i1-i58.
8. Aksamit TR, Carretta E, Daley CL, O'Donnell AE, Thomashow B, Dominik R, Olivier KN, Knowles MR, Griffith DE, Barker AF, et al. The Bronchiectasis Research Registry: a collaborative research cohort for non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012; 185:A3654.
9. Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, Poppelwell L, Salih W, Pesci A, Dupont LJ, et al. The bronchiectasis severity index: an international derivation and validation study. Am J Respir Crit Care Med 2014;189:576-585.
10. Tunney MM, Einarsson GG, Wei L, Drain M, Klem ER, Cardwell C, Ennis M, Boucher RC, Wolfgang MC, Elborn JS. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med 2013; 187:1118-1126.
11. Aksamit TR, Philley JV, Griffith DE. Nontuberculous mycobacterial (NTM) lung disease: the top ten essentials. Respir Med 2014;108: 417-425.
12. Mart́inez-Garćia MA, de la Rosa Carrillo D, Soler-Cataluña JJ, Donat-Sanz Y, Serra PC, Lerma MA, Ballest́in J, Ś anchez IV, Selma Ferrer MJ, Dalfo AR, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;187:823-831.